Artal Group S.A. Lexicon Pharmaceuticals, Inc. Transaction History
Artal Group S.A.
- $188 Million
- Q3 2025
A detailed history of Artal Group S.A. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 136,180,481 shares of LXRX stock, worth $193 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
136,180,481
Previous 136,180,481
-0.0%
Holding current value
$193 Million
Previous $129 Million
45.26%
% of portfolio
100.0%
Previous 100.0%
Shares
8 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
227MCall Options Held
2.5MPut Options Held
271K-
Siren, L.L.C. New York, NY38.9MShares$55.3 Million2.06% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.52MShares$13.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.83MShares$5.44 Million0.0% of portfolio
-
Sessa Capital Im, L.P. New York, NY3MShares$4.26 Million0.1% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $268M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...